reason report
elimin ptab overhang de-risk tecfidera significantli
pt
bottom line tecfidera patent trial appeal board ptab
decis today clearli great news signific posit
upsid surpris invest commun result stock
close assum coverag name day
ago link assum signific downsid scenario
gener tecfidera entri also point
stock upsid tecfidera patent held given
stock move appear investor believ district court
similar outcom today ipr rule howev investor
discuss also clear mani investor wait
sidelin tecfidera event clear could stock
aducanumab opportun henc hard know much
upward move came believ messag
clear investor believ tecfidera ip risk
diminish assum product protect
model result pt increas
recommend remain aggress stock reiter
what new today ptab issu decis favor
state mp shown suffici evid
challeng claim patent tecfidera unpatent
time tecfidera patent challeng
ipr held time increas
chanc decis occur district court
notabl discuss pre-ipr decis medacorp ip
lawyer knowledg tecfidera ip case lawyer believ
low likelihood ipr decis side
howev indic ipr board often lower bar
evid rule patent even could
prove case ipr decis would lower likelihood
gener compani win district court case
higher bar evid overal believ win ipr case
probabl meant would win district court case well
contribut decis chang model substanti
acknowledg opposit end risk
spectrum regard tecfidera profit forecast model
assum best case scenario yet still district court case
outstand west virginia delawar trial set readout
trial never realli know outcom final
decis manag look smart today settl
hindsight aggress share buy-back past
sotp analysi forecast cash
flow discount
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
year look like anoth good decis regard use capit still
possibl manag may choos settl two outstand
district court case gener player give small amount
patent runway would downsid model
live risk especi sinc believ
upper hand negoti thu would expect potenti
short hit tecfidera loe period model year tecfidera
sale worth stock overal also believ
way compani handl issu concern result
volatil stock past year help boost investor
confid manag team broader strateg level
chang model extend tecfidera loe
increas total tecfidera franchis tecfidera
vumer peak us sale
nearli doubl estim peak us sale vumer
part franchis would
like benefit favor tecfidera ip posit vumer sale
forecast may still appear somewhat conserv physician
discuss believ excit isnt vumer
henc remain cautiou increas tecfidera spend keep
expens ratio franchis flat slightli addit
year patent life much differ signific declin
previous model assum manag would
aggress manag profit franchis downsid
scenario net result chang ad pt
invest thesi four-fold
believ aducanumab better chanc get approv earli
alzheim diseas ad becom signific product peak sale yet
stock reflect po
valuat alreadi reflect signific spinraza declin due new competit
assum best case scenario tecfidera gener entri base
durabl base busi profit stream multipl sclerosi ms franchis
royalti biosimilar remain underappreci provid capit alloc option
pipelin get minim attent valu attribut thu good news
portfolio drive upsid valuat
pt base sum-of-the-part sotp analysi forecast cash flow
discount rate
risk invest thesi
aducanumab approv fda
new safeti signal aducanumab detect practic hinder commerci uptak
base busi deterior wors expect
tecfidera gener entri happen
spinraza declin even faster forecast
early-stag pipelin product fail late-stag studi
ms demyelin
ad alzheim diseas xlrp x-link retin pigmentosa cia cognit impair associ schizophrenia al amyotroph later sclerosi
sale growth growth growth growth rate growth growth biosimilar growth rate growth growth sale growth growth excl ad sale eisai growth growth biogen inc
 oper activitiesnet incom oper asset liabil use oper invest activitiescapit market intangibles/aquir busi ionis/samsung consider fumapharma invest use invest financ activitiesnet chang distribut non-control consider incl payment use financ equival begin equival end inc
 balanc sheet asset receiv current current equip tax stockhold equitycurr liabilitiesaccount payabl accru tax debt current portion lt expens current term tax long term equitypref paid-in comprehens stockhold liabil stockhold biogen inc
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori biogen inc
leerink place outperform rate novemb
creat bluematrix
pt base sum-of-the-part sotp analysi forecast cash flow
risk valuat
risk invest thesi
aducanumab approv fda
new safeti signal aducanumab detect practic hinder commerci uptak
base busi deterior wors expect
tecfidera gener entri happen
spinraza declin even faster forecast
early-stag pipelin product fail late-stag studi
rate price target histori
leerink place outperform rate novemb
creat bluematrix
use weight averag ev/ebitda multipl ebitda deriv price target
per share valuat includ cash outflow base estim pv potenti damag
relat on-going opioid gener price fix lawsuit
risk valuat
gener advair opportun may smaller estim commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr gener copaxon may
improv biosimilar neulasta ramp may slower estim remedi morgantown facil
may take longer allevi reach lower capac current estim mylan/upjohn deal may yield
expect revenu growth synergi expect
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
